abstract |
The present invention relates to the use of glutaminyl cyclase (QC) as a diagnostic / prognostic indicator for the treatment of neurodegenerative diseases such as Alzheimer's disease (AD), mild cognitive impairment (MCI), and Down's Syndrome (NDS) Diagnosing, or predicting a disease. The use of antibodies that bind to QC and kits for performing the diagnostic methods are also provided. |